Floatz logo

CLEMASTIN

Chronic Urticaria

NovartisSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Chronic Urticaria cohort.

Asset / SponsorPhaseRating
Loratadine
Novartis
Phase 2B
Omalizumab
Novartis
Phase 2B

Same molecule, other indications

CLEMASTIN is also rated in:

relapsing-remitting multiple sclerosisDormant
B
Indicative ·
61 / 100
View asset →
multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →
internuclear ophthalmoplegiaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →